The human D 4 receptor gene (D4DR) was initially cloned from human neuroblastoma cells using probes complementary to mRNA sequences required to synthesize D 2 receptor proteins, and was found to encode a protein product typically containing 387 amino acids. with an initial external amino terminus and final intracellular segment ending with a carboxy moiety. The third intracellular cytoplasmic loop (IL 3 ) of the receptor peptide chain between the proposed fifth and sixth transmembrane segments (TM V , TM VI ) and the intracytoplasmic carboxyl terminal segment are believed to couple to G-proteins and interact with other molecular elements involved in DA-mediated synaptic neurotransmission.
with an initial external amino terminus and final intracellular segment ending with a carboxy moiety. The third intracellular cytoplasmic loop (IL 3 ) of the receptor peptide chain between the proposed fifth and sixth transmembrane segments (TM V , TM VI ) and the intracytoplasmic carboxyl terminal segment are believed to couple to G-proteins and interact with other molecular elements involved in DA-mediated synaptic neurotransmission. 3 Indeed, the molecular differentiation of the five main members of the DA receptor family is based largely on the length and amino acid sequences of IL 3 and the intracellular carboxy terminal segment. 1 The D 4 receptor protein contains several post-translationally modifiable elements common to D 2 -like DA receptors, including at least one potential site for Nlinked glycosylation in the extracellular amino terminus, several likely phosphorylation sites in IL 3 that may act as targets for protein kinases A and C, a cysteine residue at the end of the carboxyl terminal segment, two serine residues in the third cytoplasmic domain that may provide positive charge involving in 'docking' of the electronegative catechol groups of DA, and two acidic aspartate residues within TM II and TM III that may account for docking of the amino group of DA. 1, 3 Additional features include disulfide bridging of TM III and TM IV that may contribute to the stability of a proposed cup-like arrangement of the D 4 receptor protein in the lipid membrane environment. 5 The D 4 receptor peptide sequence also contains several putative domains (the Src homology 3 [SH3] binding regions that strongly interact with small adapter peptides, including Grb2 and Nck, required for full func-tional activity of G-protein coupled receptors. 6 Finally, a methionine residue located in TM VI and adjacent to phospholipid headgroup may be involved in facilitating the methylation of membrane phospholipids. 7 The rat D 4 gene was cloned after the initial work with the human DRD4 gene, 8 and found to encode a slightly shorter protein of 368 amino acids (19 fewer) than the human D 4 receptor, and without a 48-amino acid repeat sequence found in the human IL 3 region. The rat D 4 receptor also has one fewer exons (n = 4) and introns (n = 3) than the human D4DR. However, it shares with the human D 4 receptor 73% overall sequence homology and 89% homology within the seven putative TM domains. 8 
Polymorphisms of dopamine D 4 receptor genes
During its synthesis, the human D 4 
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Several genetic linkage studies have tried to associate D4DR variants with specific neuropsychiatric disorders. Most have failed to find conclusive evidence of linkage between D4DR and schizophrenia, Tourette's syndrome, bipolar manic-depressive disorder, alcoholism or drug abuse. [13] [14] [15] [16] [17] [18] [19] Other studies have suggested associations between the 7-repeat allele of D4DR and disorders including attention deficit hyperactivity disorder (ADHD), [20] [21] [22] major depressive disorder, 23 and Parkinson's disease, 24 or personality traits including 'novelty seeking'. 25, 26 All of these potentially interesting proposals concerning associations of the D4DR gene and its structural variants to clinical conditions remain inconclusive, in part, perhaps, owing to variations in the statistical analyses and other methods used.
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Expression of brain D 4 receptor mRNA
Considerable variation has been found in D 4 receptor mRNA expression between brain regions and species. In rat brain, the highest concentrations of D 4 mRNA arise in frontal cortex, thalamus and hypothalamus. 3, 8 Mouse brain has highest levels in cerebellum, followed by frontal cortex, caudate-putamen (CPu) and thalamus. 27 In monkey brain, relatively high levels of D 4 mRNA expression occur in frontal cortex, amygdala and medulla oblongata. In human brain, localization of D 4 mRNA is more controversial, as several studies attempting to define its regional distribution in undiseased human brain tissue have yielded inconsistent results. [28] [29] [30] [31] [32] Overall, these studies suggest that greater expression of D 4 mRNA occurs in cortical and limbic regions of human forebrain, with variable levels in cerebellum and thalamus, and substantially lower amounts in the basal ganglia.
Inconsistencies in estimating D 4 mRNA levels have also arisen in studies comparing postmortem brain tissue from patients diagnosed with schizophrenia or normal controls. One study found significant elevation of D 4 mRNA expression in frontal cortex of schizophrenic patients, 33 two others found no differences, 34, 35 and a fourth found substantially reduced levels in the orbitofrontal cortex of schizophrenic patients. 31 Such inconsistencies may arise from multiple sources, including clinical heterogeneity in both patients and controls, and variance in postmortem delay, tissue handling, and assay procedures. 41 In diseased postmortem human tissue, several studies using such radioligand binding methods reported significantly higher D 4 receptor-density in CPu tissue from subjects diagnosed with schizophrenia than in normal controls. [36] [37] [38] Again, others failed to replicate these findings. 40, 42, 43 A recent analysis with the D 4 -selective radioligand [ 3 H]NGD 94-1, detected no changes in radioligand binding in postmortem CPu tissue from brains of normal controls and patients with schizophrenia. 41 These findings require further verification with other highly D 4 -selective radioligands as they become available, and testing for specificity in comparisons with other subjects diagnosed with major mental illnesses other than schizophrenia.
Detection of brain D 4 receptor protein
Radioligand assays
In 48 D 4 receptors in rat CPu seem to have a particularly intriguing anatomical localization. We found that a subset of them co-localizes with glutamate receptors of the N-methyl-d-aspartic acid (NMDA) type on terminals of corticostriatal projections innervating the basal ganglia, or perhaps on parallel fibers projecting from cortical layer V where the majority of glutamatergic corticostriatal projections originate. 46, 49, 50 This proposed co-localization of NMDA and D 4 receptors seems to be limited to terminals of corticostriatal projections, but not the projections from hippocampus to CPu and NAc. 51 Thus, hippocampal lesioning localized NMDA and kainate, but neither D 4 nor other DA receptors on rat hippocampostriatal projection terminals. 52, 53 Degeneration of DA afferents projecting from substantia nigra to CPu further indicated that D 4 autoreceptors are unlikely to be found with presynaptic D 2 /D 3 autoreceptors or ionotropic glutamate NMDA, AMPA and kainate heteroceptors at nigrostriatal projection terminals. 46, 49, 50, 54 Immunological assays Development of D 4 -selective antibodies provides another approach to selective localization of D 4 receptor proteins in brain tissue. A specific monoclonal antibody raised against the extracellular amino-terminal of the human D 4 receptor labeled cerebral cortex and substantia nigra. 55 In nonhuman primate brain, another D 4 receptor-antibody raised against the amino terminal of the human D 4 receptor labeled GABA-containing interneurons, and pyramidal glutamatergic neurons in cerebral cortex, hippocampus, thalamic reticular nucleus, and globus pallidus. 56 In rat brain, D 4 -selective polyclonal antibodies generated against a specific fragment in the amino terminal of rat D 4 receptor indicated significant densities of D 4 receptors in frontal cortex, followed by thalamus, globus pallidus, and hippocampus, with lesser amounts in CPu. 57 Another immunocytochemical study using different D 4 antibodies generated against a selective segment from the third intracellular loop of rat D 4 receptor indicated a wider distribution of D 4 receptors in rat brain, including substantial levels in CPu and NAc. 58 Such differences in D 4 receptor localization may stem from differences in the specific epitopic peptide sequences used to generate antibodies against D 4 receptor protein.
Positron-emission tomography (PET)
PET imaging was recently introduced for labeling D 4 receptors in vivo. In primate brain, specific binding signals for D 4 receptors were detected by PET in frontal, temporal, parietal and occipital lobes of cerebral cortex, as well as in CPu. 59 7 In contrast to their ability to reduce cAMP production in mammotrophic cell lines derived from pituitary lactotrophs, stimulation of the three main human D 4 receptor variants in transfected mammotrophs neither altered the activity of the prolactin promoter region necessary for regulation of prolactin gene transcription nor increased prolactin secretion. 65 Studies of genetically altered, D 4 -knockout mice also support a role for D 4 receptors in modulating normal and psychostimulant-induced motor behaviors. Notably, such D 4 -deficient mice were found to be more responsive to locomotor-stimulating effects of ethanol, cocaine, and methamphetamine. 66 This
D 4 receptors and antipsychotic drugs
Several laboratories have confirmed the initial observation by Van Tol and his colleagues 3 that the unusual antipsychotic agent clozapine has some selectivity for D 4 over D 2 and other DA receptors. 45, 68, 69 These findings stimulated the hypothesis that actions by clozapine at D 4 receptors may contribute to its status as an atypical and unusually effective antipsychotic agent. Clozapine virtually lacks risk of adverse extrapyramidal motor effects (dystonia, parkinsonism, tardive dyskinesias) characteristic of most typical neuroleptics, and remains unique in having substantial evidence of superior effectiveness to standard antipsychotics, particularly in patients with treatmentresistant schizophrenia and perhaps severe schizoaffective and bipolar disorders. [70] [71] [72] Olanzapine, a recently introduced structural analog of clozapine, shares with clozapine some D 4 -over-D 2 selectivity. 68, 73 However, other clozapine-like analogs including quetiapine and loxapine do not share the D 4 -over-D 2 selectivity. 68, 73 In addition, other innovative antipsychotic drugs including melperone, remoxipride, risperidone, sertindole and ziprasidone are not D 4 -selective, indicating that preferential selectivity for D 4 receptors does not uniquely distinguish atypical antipsychotics from typical neuroleptics. 68, 69, 74 Many of these other atypical agents are, notably, also strongly antiserotonergic. 75 In addition, some S(+) enantiomers of the classic DAagonist R(−)-aporphines, and particularly S(+)-N-n-propylnorapomorphine (S [+] candidates as common sites of antipsychotic drug action, that might guide development of novel psychotropic agents.
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D 4 -selective agents
A growing number of novel compounds with much greater D 4 selectivity over other DA receptors than that of clozapine have been developed recently. 18, 87, 88 Among the earliest D 4 -selective antagonists reported were L-745,870, 89 and its iodinated congener L-750,667. 90 Other chemically novel D 4 -selective agents usually considered D 4 antagonists (Figure 1) 102 In addition, at least two novel D 4 receptor agonists have been developed (Figure 2 ): PD-168,077 103 and CP-226,269 104 although the balance of antagonist/ agonist activity of some agents usually considered antagonists has been challenged recently, 105, 106 and whereas selectivity for D 4 over other D 2 -like receptors has held up, interactions at other sites have emerged. 18 These include high affinity of L-745,870, L-750,667 and PNU-101958 for so-called sigma sites ( 1 'receptors'), whose functional status remains unclear. 90, 95, 107 All of the new D 4 -selective compounds exhibit high D 4 receptor-affinity (0.3-8.7 nM Ki values), as well as high selectivity for D 4 sites over other DA receptor types ( Table 2) . One of these compounds has been tritiated ([ 3 H]NGD 94-1) and used for autoradiographic visualization of D 4 receptors in rat 48 and human postmortem brain tissue. 41 However, this radioligand has limitations in terms of its relatively low specific radio activity, long periods of exposure to tritium-sensitive films (3 months in rats), 48 and it is not available commercially. Three other D 4 -selective radioligands 95, 107 The 1 sites probably can be masked with agents such as ditolyguanidine to avoid inaccurate interpretation of radioligand binding. 95 Important challenges in developing radioligands for D 4 Behavioral effects of several D 4 -selective compounds were evaluated in animal models believed to be predictive of antipsychotic activity, including blockade of motor hyperactivity induced by DA agonists (eg, R[−]-apomorphine) and releasers (eg, [+] -amphetamine), inhibition of conditioned avoidance responses, inhibition of climbing elicited by apomorphine, or reversal of deficits in prepulse inhibition (PPI) of acoustic startle responses. 109 Behavioral tests indicative of extrapyramidal side effects have also been used, including induction of catalepsy, inhibition of gnawing elicited by methylphenidate, and development of 'vacuous-chewing' jaw movements after long-term administration of a test agent. 110, 111 Both L-745,870 and S 18126 neither induced catalepsy nor inhibited methylphenidate-induced gnawing. 100, 112 However, they failed to induce significant changes in behavioral tests predictive of antipsychotic efficacy, suggesting that these compounds may neither display antipsychotic-like activity nor induce adverse extrapyramidal motor effects. 100, 112 Moreover, pretreatment with L-745,870 neither altered the discriminative stimulus property of cocaine nor modified the behavioral arousal induced by this stimulant. 113 Other D 4 -selective agents showed various behavioral effects. For example, NGD 94-1 reversed deficits in an object retrieval-detour behavioral paradigm in monkeys produced by repeated pretreatment with the psychotomimetic drug phencyclidine. 114 PNU-101387G blocked amphetamine-induced behavioral sensitization and apomorphine-induced PPI deficits, but did not affect acute behavioral activation induced by apomorphine or amphetamine. 93, 115 CP-293,019 and NRA-0045 did not induce catalepsy or block apomorphineinduced stereotypy. In addition, both compounds attenuated hyperlocomotion induced by DA agonists and significantly reversed apomorphine-induced disruption of PPI. 96, 97, 116, 117 The findings suggest that these compounds may have potential for clinical psychotropic activity with a low risk of extrapyramidal motor effects associated with effective D 2 receptor blockade that seems to be characteristic of all typical neuroleptics. 1, 17 Surprisingly, preliminary clinical trials with at least two agents with D 4 -over-D 2 selectivity have failed to indicate any evidence of antipsychotic benefits. L-745,870 showed lack of improvement, or even slight worsening, in psychotic symptoms of 26 hospitalized, acutely psychotic schizophrenic patients compared to 12 others given only a placebo. 118 The results are hard to interpret since effects of carry-over or withdrawal of previous medication were not necessarily precluded by the brief (3-to 5-day) placebo run-in period involved. 
